Compounded Semaglutide in 2026: FDA Status and Safety Checks

What Changed

• FDA determined the semaglutide injection shortage was resolved in February 2025.
• FDA states that shortage-related enforcement discretion has ended for state-licensed pharmacies or physicians operating under section 503A.
• For outsourcing facilities under section 503B, FDA's shortage-related enforcement-discretion period ended May 22, 2025.
• On February 6, 2026, FDA announced intended enforcement against mass-marketed, non-FDA-approved compounded GLP-1 products and misleading claims.
• On March 3, 2026, FDA announced warning letters to 30 telehealth companies over false or misleading compounded GLP-1 marketing.
• On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances. That was a proposal, not a final rule.

What the End of a Shortage Means

When an approved drug is on FDA's shortage list, some federal restrictions on making products that are essentially copies may not apply. When the shortage ends, those shortage-specific flexibilities end according to the FDA timetable.

This does not make every patient-specific compounded prescription automatically unlawful. FDA says a compounded drug might be appropriate when a patient's medical need cannot be met by an FDA-approved drug or the approved drug is not commercially available. Sections 503A and 503B contain different conditions, and state law also applies.

Safety and Marketing Concerns

FDA warns about dosing errors, fraudulent labels, improper shipping temperatures, adverse events, and products made with salt forms. As of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA notes that reports do not prove the compounded product caused the event and that underreporting is likely.

FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base used in approved products. The agency says it is not aware of a lawful basis for using those salt forms in compounding.

Marketing a compounded product as “generic Ozempic” or “generic Wegovy” is misleading. There is no FDA-approved generic version of either brand.

What to Verify

1. Prescription and medical need: A licensed prescriber issued a patient-specific prescription and can explain why an approved product does not meet the patient's need.
2. Pharmacy license: Confirm the pharmacy's license with the patient's state board of pharmacy.
3. 503A or 503B status: Ask which federal framework applies. FDA maintains an outsourcing-facility list.
4. Ingredient form: Ask whether the product uses semaglutide base rather than semaglutide sodium or acetate.
5. Concentration and measuring units: The prescription, vial, and syringe markings should be clear and consistent. A pharmacist should resolve discrepancies before use.
6. Shipping and storage: Ask how temperature is controlled and what to do if a package arrives warm, damaged, or delayed.
7. Quality complaints: Ask how the pharmacy handles product-quality concerns and adverse events.

A certificate of analysis can provide limited batch information, but it does not make a compounded drug FDA-approved or guarantee that every legal and quality requirement was met.

Cost and Coverage

There is no reliable national price range for compounded semaglutide. Prices vary by pharmacy, concentration, service bundle, state, and prescription. A low price alone cannot establish whether a product is lawful or safe.

Insurance coverage varies by plan and circumstance. Verify the current benefit directly with the insurer. Manufacturer savings programs for FDA-approved products have separate eligibility rules and can change.

Supplies

For a prescribed injectable product, a clinician or pharmacist can explain necessary supplies and disposal. Common items include alcohol prep pads and a sharps container. Do not rely on a general article to select a syringe, concentration, or dose.

Bottom Line

Semaglutide is no longer on FDA's shortage list, and shortage-related enforcement discretion has ended. Limited patient-specific compounding may still be appropriate when federal and state requirements are met, but compounded semaglutide is not FDA-approved. Verify the prescription, pharmacy, ingredient form, concentration, and shipping conditions, and avoid sellers using “generic Ozempic” or “generic Wegovy” claims.

This article is for informational purposes only and does not constitute medical or legal advice. Consult a licensed prescriber and pharmacist about an individual prescription, and check current FDA and state-board information before obtaining a compounded product.